Mepolizumab in Preventing COPD Exacerbations in Patients with Eosinophilic Phenotype: Insights from the MATINEE Trial

Study Background and Disease Burden

Chronic obstructive pulmonary disease (COPD) is a prevalent and progressive respiratory condition characterized by airflow limitation and chronic inflammation. It represents a leading cause of morbidity and mortality worldwide. A significant proportion of patients with COPD—estimated between 20% and 40%—exhibit an eosinophilic inflammatory phenotype, marked by elevated peripheral blood eosinophil counts. This subgroup tends to experience more frequent and severe exacerbations, which contribute substantially to the disease burden, impaired quality of life, and increased healthcare utilization.

The pathophysiology of eosinophilic COPD involves eosinophil-driven inflammation, mediated largely by interleukin (IL)-5—a key cytokine responsible for eosinophil differentiation, recruitment, and survival. Traditional therapies including inhaled corticosteroids (ICS), long-acting beta-agonists (LABA), and long-acting muscarinic antagonists (LAMA) provide baseline control, but exacerbations persist in this high-risk cohort.